HRP20161197T1 - 24-norudca za liječenje autoimunog hepatitisa - Google Patents

24-norudca za liječenje autoimunog hepatitisa Download PDF

Info

Publication number
HRP20161197T1
HRP20161197T1 HRP20161197TT HRP20161197T HRP20161197T1 HR P20161197 T1 HRP20161197 T1 HR P20161197T1 HR P20161197T T HRP20161197T T HR P20161197TT HR P20161197 T HRP20161197 T HR P20161197T HR P20161197 T1 HRP20161197 T1 HR P20161197T1
Authority
HR
Croatia
Prior art keywords
autoimmune hepatitis
acceptable salts
ursodeoxycholic acid
norudca
pharmaceutically acceptable
Prior art date
Application number
HRP20161197TT
Other languages
English (en)
Inventor
Michael Trauner
Alan Hofmann
Peter Fickert
Original Assignee
Medizinische Universität Graz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Universität Graz filed Critical Medizinische Universität Graz
Publication of HRP20161197T1 publication Critical patent/HRP20161197T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (3)

1. Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, naznačena/e time, da se upotrebljava(ju) u liječenju i/ili prevenciji autoimunog hepatitisa.
2. Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koja/koje se upotrebljava(ju) u liječenju i/ili prevenciji autoimunog hepatitisa prema zahtjevu 1, naznačena/e time, da se nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, formulira(ju) za oralnu, parenteralnu, subkutanu, intravenoznu, intramuskularnu, nazalnu, topikalnu ili rektalnu primjenu.
3. Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koja/koje se upotrebljava(ju) u liječenju i/ili prevenciji autoimunog hepatitisa prema zahtjevima 1 ili 2, naznačena/e time, da se nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, treba(ju) davati pacijentu u dnevnoj količini od 25 mg do 5 g, poželjno od 100 mg do 2,5 g, posebno od 800 mg do 1,5 g.
HRP20161197TT 2005-05-12 2016-09-19 24-norudca za liječenje autoimunog hepatitisa HRP20161197T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11176271.2A EP2392336B1 (en) 2005-05-12 2005-05-12 24-norUDCA for treating autoimmune hepatitis
PCT/EP2005/052178 WO2006119803A1 (en) 2005-05-12 2005-05-12 USE OF 24-nor-UDCA

Publications (1)

Publication Number Publication Date
HRP20161197T1 true HRP20161197T1 (hr) 2016-11-04

Family

ID=35457032

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20150949TT HRP20150949T1 (hr) 2005-05-12 2015-09-08 UPORABA 24-norUDCA
HRP20151091TT HRP20151091T1 (hr) 2005-05-12 2015-10-16 UPORABA 24-norUDCA
HRP20161197TT HRP20161197T1 (hr) 2005-05-12 2016-09-19 24-norudca za liječenje autoimunog hepatitisa

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HRP20150949TT HRP20150949T1 (hr) 2005-05-12 2015-09-08 UPORABA 24-norUDCA
HRP20151091TT HRP20151091T1 (hr) 2005-05-12 2015-10-16 UPORABA 24-norUDCA

Country Status (18)

Country Link
US (1) US8951995B2 (hr)
EP (4) EP2392336B1 (hr)
AU (1) AU2005331734B2 (hr)
CY (4) CY1116831T1 (hr)
DK (4) DK2392336T3 (hr)
EA (1) EA014077B1 (hr)
ES (4) ES2547127T3 (hr)
HK (1) HK1161122A1 (hr)
HR (3) HRP20150949T1 (hr)
HU (4) HUE025184T2 (hr)
LT (1) LT2392336T (hr)
ME (3) ME02544B (hr)
NO (1) NO340318B1 (hr)
PL (4) PL2392336T3 (hr)
PT (3) PT2392335E (hr)
RS (3) RS55180B1 (hr)
SI (4) SI2392337T1 (hr)
WO (1) WO2006119803A1 (hr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
TR201901012T4 (tr) * 2007-07-25 2019-02-21 Univ Graz Medizinische Arteriosklerozun tedavisinde nor-safra asitlerinin kullanımı.
EP2468762A1 (en) * 2010-11-30 2012-06-27 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
EP3461485A1 (en) 2017-09-28 2019-04-03 Dr. Falk Pharma Gmbh Use of nor-ursodeoxycholic acid for reducing liver fat
GB201911821D0 (en) 2019-08-16 2019-10-02 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds for use in the treatment of liver disease
US11372809B2 (en) * 2019-09-27 2022-06-28 Oracle International Corporation System and method for providing correlated content organization in an enterprise content management system based on a training set
WO2021130232A1 (en) 2019-12-23 2021-07-01 Medizinische Universität Wien Bile acid derivatives in the medical intervention of anxieties and/or stress symptoms
WO2024023669A1 (en) * 2022-07-25 2024-02-01 Shilpa Medicare Limited Pharmaceutical compositions of nor-udca

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892868A (en) 1984-08-17 1990-01-09 Gipharmex, S.P.A. Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
IT1229569B (it) * 1989-04-17 1991-09-04 Giuliani Spa Derivati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
IT1255449B (it) 1992-06-30 1995-10-31 Fabio Berlati Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
TW289020B (hr) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
ITMI20012572A1 (it) 2001-12-06 2003-06-06 Istituto Biochimico Italiano Microgranuli di acido ursodesossicolico

Also Published As

Publication number Publication date
SI1890705T1 (sl) 2016-02-29
EP2392335A2 (en) 2011-12-07
CY1116831T1 (el) 2017-03-15
PT2392337E (pt) 2015-11-02
EP2392336B1 (en) 2016-06-22
CY1117174T1 (el) 2017-04-05
NO20076405L (no) 2008-02-11
HUE025184T2 (en) 2016-01-28
US8951995B2 (en) 2015-02-10
EP2392337B1 (en) 2015-07-29
WO2006119803A1 (en) 2006-11-16
EA014077B1 (ru) 2010-08-30
EP2392335B1 (en) 2015-06-24
RS54185B1 (en) 2015-12-31
SI2392337T1 (sl) 2015-10-30
ME02544B (me) 2017-02-20
EP1890705A1 (en) 2008-02-27
EP2392336A2 (en) 2011-12-07
AU2005331734A1 (en) 2006-11-16
ES2590333T3 (es) 2016-11-21
SI2392336T1 (sl) 2016-10-28
EA200702336A1 (ru) 2008-04-28
ES2561614T3 (es) 2016-02-29
EP1890705B1 (en) 2015-11-11
EP2392336A3 (en) 2011-12-28
DK2392337T3 (en) 2015-09-28
CY1117959T1 (el) 2017-05-17
CY1116840T1 (el) 2017-03-15
ES2550204T3 (es) 2015-11-05
EP2392337A2 (en) 2011-12-07
HUE030010T2 (en) 2017-04-28
HRP20150949T1 (hr) 2015-12-04
ME02737B (me) 2015-12-31
NO340318B1 (no) 2017-03-27
HUE025409T2 (en) 2016-02-29
PL2392336T3 (pl) 2016-12-30
EP2392337A3 (en) 2012-01-04
ME02256B (me) 2015-12-31
SI2392335T1 (sl) 2015-10-30
HK1161122A1 (en) 2012-08-24
PT2392336T (pt) 2016-10-04
RS54140B1 (en) 2015-12-31
DK2392335T3 (en) 2015-06-29
US20090163459A1 (en) 2009-06-25
EP2392335A3 (en) 2011-12-28
PT2392335E (pt) 2015-10-06
PL2392337T3 (pl) 2015-12-31
AU2005331734B2 (en) 2012-04-19
LT2392336T (lt) 2016-10-10
HRP20151091T1 (hr) 2015-11-06
PL2392335T3 (pl) 2015-10-30
DK1890705T3 (en) 2016-02-01
PL1890705T3 (pl) 2016-05-31
ES2547127T3 (es) 2015-10-01
DK2392336T3 (en) 2016-09-05
HUE028336T2 (en) 2016-12-28
RS55180B1 (sr) 2017-01-31

Similar Documents

Publication Publication Date Title
HRP20161197T1 (hr) 24-norudca za liječenje autoimunog hepatitisa
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2007133637A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
TW200638935A (en) Pyridazine derivatives and their use as therapeutic agents
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
WO2005112967A3 (en) Anticancer activity of chios mastic gum
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
ATE466574T1 (de) Verfahren und zusammensetzungen zur oralen fts- abgabe
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
JP2007119497A5 (hr)
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases